Scotland · NHS Scotland MSAN
Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches - Update
MSAN(2026)18 · Level 2 · issued 12 Jun 2026
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| 1. Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches are in limited supply until | Limited supply | — |
| 2. Rivastigmine 13.3mg/ 24hours transdermal patch remains available but cannot support an uplift | Available — cannot support uplift | — |
| 3. Rivastigmine (Zeyzelf) twice weekly 4.6 mg/24hours transdermal patch remains available but | Available | — |
| cannot support an uplift in demand. | Available — cannot support uplift | — |
| 4. Rivastigmine (Zeyzelf) twice weekly 9.5 mg/24hours transdermal patch remains available but | Available | — |
| cannot support uplift in demand. | Available — cannot support uplift | — |
| are available. | Available | — |
| 7. Alternative formulations of acetylcholinesterase (AChE) inhibitors remain available, except for | Available | — |
| galantamine modified release capsules which are also in limited supply (see Additional | Limited supply | — |
| 11. Of the AChE inhibitors, only rivastigmine is available as a transdermal formulation. | Available | — |
| you need to register with the SPS website. Registration for access to the website is available to | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.